Alopecia (Baldness)

Subscribe to Selected New Research on Alopecia

2443 relevant articles (155 outcomes, 186 trials/studies) found for this Disease

Description: Absence of hair from areas where it is normally present.

Also Known As:

Baldness; Androgenetic Alopecia; Male Pattern Baldness; Alopecia, Male Pattern; Baldness, Male Pattern; Male Pattern Alopecia; Alopecia, Androgenetic; Pseudopelade

Relationship Network

Disease Context: Research Results

Skin and Connective Tissue Diseases

Follicular Mucinosis: 38

Signs and Symptoms Pathological Conditions

Anatomical Pathological Conditions

Alopecia: 2443

Related Diseases

1.	Acne Vulgaris
2.	Alopecia Areata
3.	Nausea
4.	Hirsutism
5.	Breast Neoplasms (Breast Cancer)

Experts

1.	Tsuruki, Takahiro: 7 articles (05/2007 - 03/2004)
2.	Yoshikawa, Masaaki: 7 articles (05/2007 - 03/2004)
3.	Kaufman, Keith D: 5 articles (07/2008 - 04/2002)
4.	Frank, Linda A: 4 articles (08/2006 - 04/2003)
5.	Paus, Ralf: 3 articles (09/2007 - 01/2004)
6.	Takahata, Kyoya: 3 articles (05/2007 - 03/2004)
7.	Tosti, A: 3 articles (05/2005 - 10/2000)
8.	Sinclair, R D: 3 articles (10/2002 - 05/2000)
9.	Khumalo, N P: 2 articles (12/2007 - 03/2007)
10.	Ngwanya, R M: 2 articles (12/2007 - 03/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Alopecia:

1.	Minoxidil (Rogaine)FDA LinkGeneric 05/01/2000 - "The best treatment option for women with androgenetic alopecia Ludwig stage I and II is minoxidil 5% solution" 02/01/2002 - "After more than a decade of use, topical minoxidil solution has proven to be a safe and effective treatment for androgenetic alopecia" 03/01/1994 - "CONCLUSIONS: Topical minoxidil was significantly more effective than placebo in the treatment of female androgenetic alopecia." 10/01/1993 - "Topical minoxidil solution was significantly more effective than placebo in the treatment of androgenetic alopecia in women." 05/01/1986 - "It was concluded that topical minoxidil has the potential to improve male pattern baldness significantly without apparent risk and to be a means by which individual presentation of self may be improved." Order ALL the reference details at left...
2.	Finasteride (Propecia)FDA LinkGeneric 01/01/2008 - "No study has shown that 1 mg of finasteride effectively treats female androgenetic alopecia but doses of 2.5 and 5 mg finasteride have helped some women in a few open studies" 05/01/2008 - "BACKGROUND: Finasteride is a 5alpha-reductase inhibitor that has proved to be an effective treatment for men with androgenetic alopecia" 08/01/2002 - "Finasteride 1 mg/day is effective in the treatment of androgenetic alopecia (AGA)" 07/01/2001 - "Finasteride has been shown to be an effective treatment for men with androgenetic alopecia (AGA) as it restores hair growth to miniaturized hair follicles on the top of the scalp [1]" 06/01/1998 - "Type II, also present on the scalp, is the target of finasteride, a promising treatment for male pattern baldness" Order ALL the reference details at left...
3.	Doxorubicin (Adriamycin)FDA LinkGeneric 11/01/1990 - "This led to a partial remission of two-years duration and the abatement of a doxorubicin-induced alopecia" 12/01/1983 - "An improved "ice-cap" to prevent alopecia caused by adriamycin (doxorubicin)." 10/01/1996 - "The present studies were undertaken to topographically localize the site of injury in the hair follicle after doxorubicin (DXR) administration and to investigate the mechanism of DXR-induced alopecia" 10/01/1986 - "Preliminary studies are reported on the effectiveness of cold air scalp cooling to prevent alopecia in patients receiving Adriamycin" 04/01/2006 - "Doxorubicin-induced alopecia is associated with sebaceous gland degeneration." Order ALL the reference details at left...
4.	Cyclophosphamide (Cytoxan)FDA Link 08/01/2001 - "PTH(7-34) and PTHrP(7-34) shifted it towards a mild form of "dystrophic anagen", associated with a significant reduction in apoptotic (TUNEL+) hair bulb cells, thus mitigating the degree of follicle damage and retarding the onset of cyclophosphamide-induced alopecia" 01/01/1987 - "Good results were obtained though the course included cyclophosphamide which also causes alopecia" 07/01/2008 - "on cyclophosphamide-induced alopecia (CIA) in C57BL/6 mice, these strategies remain to be transferred to human therapy" 07/01/2005 - "A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice." 12/19/2001 - "AdShh treatment of 3-week-old mice with cyclophosphamide-induced alopecia was followed by accelerated hair follicle recovery (19 of 22 mice); such recovery was not observed at this rate in AdNull-treated or naive skin (P<.001 for both comparisons)" Order ALL the reference details at left...
5.	Cytarabine (Cytosar-U)FDA LinkGeneric 07/01/1991 - "In the present study, using the young rat model, recombinant human IL 1 beta produced excellent protection from cytosine arabinoside-induced alopecia" 11/01/1992 - "All rates treated with ARA-C alone developed complete body alopecia" 01/15/1992 - "In other experiments the administration of acidic FGF (aFGF) with ARA-C resulted in protection from alopecia limited to the site of FGF injection" 01/01/1986 - "Plasma Ara-C concentrations were assayed by HPLC and the peak level was 6.7 micrograms/ml. Side effects were mild nausea, vomiting, alopecia and moderate skin rash." 06/15/1991 - "Interleukin 1 offered excellent protection against alopecia induced by ara-C but not that produced by CYC in the newborn rat animal model." Order ALL the reference details at left...
6.	Cyproterone AcetateIBA 01/01/1989 - "The therapeutic results warrant the conclusion that cyproterone acetate seems to be effective in androgenetic alopecia in women." 01/01/1989 - "The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females." 12/01/2002 - "We report a 66-year-old lady taking 50 mg/day of cyproterone acetate for biopsy proven androgenetic alopecia, who developed this unusual complication of shortness of breath" 12/01/2002 - "Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia." 01/01/2002 - "While androgenetic alopecia is best treated with a low-dose OC containing cyproterone acetate (optimal effect occurs after at least 12 months of therapy), severe acne and hirsutism are significantly improved after 6-12 months of regimens containing high doses of cyproterone acetate (25-100 mg/day)" Order ALL the reference details at left...
7.	ImuVertIBA 02/01/1992 - "Both ImuVert and IL 1 were equally effective in protecting rats from ARA-C-induced alopecia" 07/01/1991 - "It is concluded that the protection from alopecia by ImuVert is mediated by cytokines, primarily IL 1." 07/01/1991 - "Protection from cytosine arabinoside-induced alopecia by ImuVert has recently been reported in a rat model" 09/28/1990 - "In recent work on the treatment of myelogenous leukemia in the rat, the following observations were made: (i) treatment of 8-day-old rats with cytosine arabinoside consistently produced alopecia, and (ii) ImuVert, a biologic response modifier derived from the bacterium Serratia marcescens, uniformly produced complete protection against the alopecia" 02/01/1992 - "ImuVert, a biologic response modifier, and interleukin 1 (IL 1) have been shown to protect the young rat from alopecia induced by cytarabine (ARA-C)" Order ALL the reference details at left...
8.	pegylated liposomal doxorubicinIBA 01/01/1997 - "Recently published data from a phase II trial in patients with refractory ovarian cancer showed no alopecia or cardiotoxicity and little nausea and vomiting after pegylated liposomal doxorubicin" 01/01/2003 - "The toxicity profile of pegylated liposomal doxorubicin is characterised by dose-limiting mucosal and cutaneous toxicities, mild myelosuppression, decreased cardiotoxicity compared with free doxorubicin and minimal alopecia" 01/01/2008 - "Pegylated liposomal doxorubicin (Doxil((R)), Caelyxtrade mark) is associated with less frequent neutropenia, alopecia and cardiotoxicity than conventional doxorubicin and has an improved pharmacokinetic profile, allowing for intravenous administration over 1 hour" 12/01/2003 - "Pegylated liposomal doxorubicin provides tumor-targeted efficacy without many of the toxicities associated with conventional doxorubicin, including myelosuppression, alopecia, nausea and vomiting, and most importantly, cardiac toxicity" 01/01/1997 - "Thus, the rationale for the use of pegylated liposomal doxorubicin in solid tumours may be summarised as follows: change in the toxicity profile with a decrease in acute adverse effects (such as nausea and vomiting) and reduced incidence of alopecia, greater activity in highly angiogenic tumours (such as Kaposi's sarcoma) and effective treatment of tumours moderately sensitive to doxorubicin (such as breast and ovarian carcinomas), with the possibility of increased tumour response because of enhanced drug accumulation" Order ALL the reference details at left...
9.	Dihydrotestosterone (Androstanolone)IBA 01/01/2009 - "Currently, the predominant hypothesis explains androgenetic alopecia (AGA) as a process reliant upon affected follicles being individually programmed to accumulate dihydrotestosterone (DHT), which then causes progressive follicular miniaturisation" 09/01/2005 - "Dihydrotestosterone is the main molecule responsible for androgenic alopecia" 05/01/2004 - "Although it is universally accepted that dihydrotestosterone causes baldness, how it does so is not well understood" 10/01/2003 - "The future may release on medical treatment avoiding dihydrotestosterone to act on genetically predisposed follicles avoiding miniaturization of the hair and baldness development" 08/01/2003 - "BACKGROUND: It is generally believed that dihydrotestosterone is one of the pivotal mediators of hair loss in androgenetic alopecia (AGA)" Order ALL the reference details at left...
10.	HormonesIBA 04/01/2003 - "Results of this study suggest that the pathomechanism of the alopecia, at least for some breeds, may not relate to steroid hormone intermediates and emphasizes the need for breed specific normals." 03/01/2000 - "OBJECTIVE: To study the role of sex hormone receptor capacity of the scalp in male pattern baldness(MPB)" 04/01/1991 - "Hormone studies in androgenetic alopecia in the female]" 02/01/1990 - "The difference in the cellular response to the hormone between the normal hair follicle cells and those from a patient were clear and easily distinguished, and these studies may provide a basis for the rapid diagnosis of DDR-II. Large number of hairs were difficult to obtain from patients with alopecia, and we developed a new culture method to accomplish these studies" 01/01/2008 - "Female sex hormone in the migraineur may be the key factor, comparable to the male sex hormone: androgen, in the genetic baldness" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 11/01/2006 - "PURPOSE: The goal is to provide an overview on the advances in protection against chemotherapy-induced alopecia (CIA)" 11/01/2006 - "Protection against chemotherapy-induced alopecia." 07/01/2004 - "However, chemotherapy-associated side effects such as appetite, alopecia, emotional stability, and general weakness were all improved by ABMK treatment" 04/01/1999 - "All patients developed grade 2 alopecia between day 20 and 30 after chemotherapy, demonstrating the lack of efficacy of topical topitriol on this schedule of administration to prevent CIA" 01/01/1995 - "METHODS AND RESULTS: Efficacy of CSA was tested in its effects on chemotherapy-induced alopecia in the newborn rat animal model" Order ALL the reference details at left...
2.	Transplants (Transplant) 10/01/2005 - "BACKGROUND: The improved scalp coverage achieved by hair transplant for men with androgenetic alopecia can be diminished by continued miniaturization and loss of preexisting, nontransplanted hairs" 11/01/1991 - "To minimize this problem, we introduced and improved a new procedure for the treatment of pattern baldness by using microsurgical hair grafts taken from the occipital region" 01/01/2008 - "Alopecia, hair transplant to recipient site and hypertrophic scarring was not encountered in our study" 09/01/2005 - "Sixty-three patients with AA, alopecia totalis, or alopecia universalis were included in this study and compared with seventy-six healthy transplant donors" 05/01/1995 - "An experiment using guinea pigs was performed to demonstrate the feasibility of repeated skin-graft harvesting as a model system in the study of diffuse alopecia" Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 09/01/2002 - "Study III: An observational study was done in 12 patients with androgenetic alopecia about 1 year after transplantation of occipital hair to frontal scalp" 07/01/2008 - "While surgical excision is preferred to hair transplantation for both categories of cicatricial alopecia, this preference is even stronger in cases of unstable cicatricial alopecia due to its intermittent and progressive nature" 01/01/2008 - "Hair transplantation can also be performed in selected cases of scarring alopecia, eyebrows and eye lashes, by experienced surgeons" 11/01/2007 - "A 57-year-old woman developed repigmentation of white donor hairs 9 months after undergoing hair transplantation for an area of frontal scarring alopecia present since childhood" 01/18/2007 - "When baldness threatens: what can be expected from hair transplantation" Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 09/01/2002 - "The aim of the study was to carry out clinical and trichological examination (trichogram and assessment of hair loss) before and after treatment in 17 women aged 41-50 years with androgenic alopecia" 01/01/2007 - "Alopecia completely reversed 2 weeks after treatment withdrawal" 06/01/1999 - "for 6 wk. After treatment, nail regrowth occurred but the multifocal areas of alopecia remained" 12/01/1990 - "After treatment with the preparation (Thymu-Skin) 73% of all cases show improvement of the alopecia" 04/01/1999 - "Signs of remission of dermatitis and alopecia became visible to the pet owners at 2 weeks after treatment" Order ALL the reference details at left...
5.	Tissue Expansion 07/01/1987 - "Male pattern baldness may be effectively eliminated in most patients through the use of soft-tissue expansion" 03/01/2008 - "The resulting alopecia area was eventually excised after tissue expansion" 08/01/2005 - "CONCLUSION: The soft-tissue expansion technique is the initiative choice and an efficient method for repairing large cicatricial alopecia." 08/01/2005 - "OBJECTIVE: To investigate the clinical application of skin soft-tissue expansion in repairing large cicatricial alopecia" 08/01/2005 - "Repair of large cicatricial alopecIa with skin soft-tissue expansion]" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Alopecia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 155 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>